Review Article

The Egyptian Journal of Immunology

The Egyptian Journal of Immunology,
E-ISSN (2090-2506)
Volume 31 (4), October, 2024
Pages: 46–57.
www.Ejimmunology.org
https://doi.org/10.55133/eji.310405

Physiology and immunology of the adrenergic anti-inflammatory pathway

Alaa A. Aboulata[1,2], and Ibrahim M. Shatla[3,4]

[1]Department of Biomedical & Dental sciences, Faculty of Dentistry, Al-Baha University, Saudi Arabia,
[2]Department of Medical Microbiology and Immunology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
[3]Department of Physiology, Faculty of Medicine, Al-Baha University, Saudi Arabia,
[4]Department of Physiology, Demietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt.

Corresponding author: Alaa A. Aboulata, Department of Biomedical & Dental sciences, Faculty of Dentistry, Al-Baha University, Saudi Arabia.
Email: aaalansari@bu.edu.sa.

Abstract

The adrenergic anti-inflammatory pathway represents a critical intersection between the nervous and immune systems, modulating the body's response to inflammation through the action of catecholamines on adrenergic receptors. This review explored the physiology underlying this pathway, focusing on the mechanisms by which the sympathetic nervous system influences immune function. We delved into the roles of specific adrenergic receptors, primarily the beta-adrenergic receptors, in mediating anti-inflammatory effects, highlighting the involved molecular signaling pathways. Additionally, we examined the immunological implications of adrenergic modulation, discussing how these pathways contributed to the resolution of inflammation and the potential for dysregulation in various disease states. Emerging evidence on the therapeutic potential of targeting the adrenergic anti-inflammatory pathway in conditions such as sepsis, autoimmune diseases, and chronic inflammatory disorders was also reviewed. By integrating current knowledge on the physiology and immunology of this pathway, this review aimed to provide a comprehensive understanding of its role in health and disease, offering insights into future research directions and clinical applications.

Keywords: Adrenergic Receptors, anti-inflammatory pathway, catecholamines, Immune Responses.

Date received: 03 June 2024; **accepted:** 27 August 2024

Introduction

Adrenergic Pathways Pharmacology and Physiology

Adrenergic pathways are fundamental to the autonomic nervous system, specifically the sympathetic branch, which orchestrates the body's fight-or-flight responses.[1] These pathways are mediated by adrenergic receptors, which are G protein-coupled receptors (GPCRs) classified into alpha (α) and beta (β) subtypes, each with distinct physiological roles and tissue distributions.[2] The activation of these receptors by endogenous catecholamines, such as norepinephrine and epinephrine, triggers a cascade of intracellular events that result in varied physiological outcomes, from increasing heart rate and blood pressure to mobilizing energy reserves during stress.[3]

The physiological relevance of adrenergic pathways extends across multiple systems,

including the cardiovascular, respiratory, and metabolic systems. In the cardiovascular system, adrenergic signaling regulates heart rate, myocardial contractility, and vascular tone, thus playing a critical role in maintaining blood pressure and ensuring adequate tissue perfusion.[4] In the respiratory system, adrenergic pathways modulate bronchial smooth muscle tone,[5] impacting airway resistance and airflow, which is particularly relevant in conditions like asthma. Additionally, these pathways influence metabolic processes, such as glycogenolysis and lipolysis, by mediating the body's response to energy demands.[6]

From a pharmacological perspective, adrenergic receptors serve as key therapeutic targets. Drugs that modulate adrenergic signaling, including adrenergic agonists and antagonists, are widely used in clinical practice to treat a range of conditions. For instance, beta-blockers are essential in managing hypertension, heart failure, and arrhythmias,[7] while beta-agonists are used to relieve bronchoconstriction in asthma.[8] The selective targeting of specific adrenergic receptor subtypes has allowed for the development of drugs with tailored effects, minimizing side effects while maximizing therapeutic benefits.

Despite the extensive understanding of adrenergic signaling, ongoing research continues to uncover new aspects of receptor function, including receptor desensitization, internalization, and crosstalk[9,10] with other signaling pathways. These insights are crucial for refining existing therapies and developing novel interventions that exploit the nuances of adrenergic receptor pharmacology.

This review aimed to provide a comprehensive overview of the physiology of adrenergic pathways, highlighting their significance in health and disease. We delved into the molecular mechanisms of adrenergic receptor action, the physiological functions they govern, and the pharmacological agents that modulate these pathways. Through this exploration, we sought to enhance the understanding of adrenergic signaling and its therapeutic potential in various clinical contexts.

Adrenergic pathways are vital to the body's ability to respond to external and internal stimuli, particularly during stress. The sympathetic nervous system, through the release of catecholamines, norepinephrine and epinephrine engage adrenergic receptors to elicit a broad range of physiological responses. These responses are not only critical for survival in acute situations but also play a significant role in maintaining homeostasis during everyday activities.[11]

Adrenergic Receptor Subtypes and Distribution



The adrenergic receptor family is characterized by its diversity and tissue-specific distribution, which allows for finely tuned physiological responses. Each subtype within the alpha (α) and beta (β) classes has unique structural and functional properties:

Alpha-1 Receptors (α1)

Alpha-1 receptors (α1) are a class of adrenergic receptors that play a crucial role in the regulation of sympathetic nervous system of various physiological functions.[12] These receptors are primarily involved in smooth muscle contraction, vasoconstriction, and other processes essential for maintaining vascular tone, blood pressure, and organ function. They are GPCRs[13] and are divided into three main subtypes: α1A, α1B, and α1D. Each subtype has unique tissue distribution, signaling mechanisms, and physiological roles.

Structure and Mechanism of Action

Alpha-1 receptors are GPCRs, meaning they are membrane-bound receptors that interact with

G proteins upon activation.[14] These receptors are coupled with the Gq family of G proteins. When a catecholamine, such as norepinephrine or epinephrine, binds to an α1 receptor, it triggers the activation of the associated Gq protein. The Gq protein then activates phospholipase C (PLC),[15] an enzyme that catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol trisphosphate (IP3) and diacylglycerol (DAG).

Inositol Trisphosphate (IP3): IP3 diffuses through the cytoplasm to the endoplasmic reticulum (ER), where it binds to IP3 receptors, causing the release of calcium ions (Ca2+) into the cytoplasm. The increase in intracellular calcium concentration is a key signal that leads to the contraction of smooth muscle cells and other cellular responses[16, 17]

Diacylglycerol (DAG): DAG remains in the plasma membrane and, along with the elevated Ca2+ levels, activates protein kinase C (PKC). PKC phosphorylates various target proteins, which can influence a range of cellular functions, including contraction, secretion, and gene expression.[18]

Alpha-1 Receptor Subtypes: Each α1 receptor subtype (α1A, α1B, α1D) is encoded by distinct genes and has different tissue distributions and physiological roles. These subtypes contribute to the fine-tuning of sympathetic nervous system responses across various organs and tissues.

Alpha-1A Receptors (α1A)

α1A receptors are predominantly found in the prostate, urethra, and bladder neck,[19] as well as in certain vascular smooth muscles, including those in the heart and cerebral arteries.

- Physiological Role: In the prostate and bladder neck, α1A receptors mediate smooth muscle contraction, which contributes to the regulation of urinary flow. Their activation leads to the constriction of the prostate and bladder neck, which can result in urinary retention. This makes α1A receptors a key target in the treatment of benign prostatic hyperplasia, where α1A antagonists (such as tamsulosin) are used to relax the smooth muscle and improve urinary flow.[20]
- Clinical Significance: α1A receptors are the primary target for uroselective α1-blockers used in the treatment of benign prostatic hyperplasia. By selectively inhibiting α1A receptors, these drugs can relieve urinary symptoms without causing significant blood pressure reduction, which is more associated with the α1B and α1D subtypes.[20]

Alpha-1B Receptors (α1B)

Tissue Distribution: α1B receptors are widely expressed in vascular smooth muscle, particularly in arteries and veins.[21] They are also present in the central nervous system (CNS), heart, and liver.

- Physiological Role: α1B receptors are primarily involved in the regulation of vascular tone and blood pressure. When activated, they cause vasoconstriction, leading to an increase in systemic vascular resistance and, consequently, blood pressure. In the CNS, α1B receptors may be involved in modulating neurotransmitter release and contributing to various behavioral responses.[21]
- Clinical Significance: The α1B subtype is implicated in the hypertensive effects of α1 agonists and some side effects of non-selective α1-blockers, such as dizziness or orthostatic hypotension. Understanding the specific role of α1B receptors can aid in the development of more targeted therapies that minimize cardiovascular side effects while retaining therapeutic efficacy.[22]

Alpha-1D Receptors (α1D)

Tissue Distribution: α1D receptors are expressed in the aorta, coronary arteries,[23] bladder, and cerebral arteries. They are also found in the spinal cord and kidneys.

- Physiological Role: In the vascular system, α1D receptors contribute to the regulation of blood flow and blood pressure by mediating vasoconstriction, particularly in large arteries like the aorta. They are also

involved in the regulation of urinary function, working in conjunction with α1A receptors in the bladder and urethra.

- Clinical Significance: α1D receptors are associated with the modulation of arterial stiffness and have been implicated in conditions such as hypertension and vascular diseases. They are also a target in the treatment of lower urinary tract symptoms, especially when selective α1-blockers are used to alleviate symptoms without affecting blood pressure significantly.[24]

Alpha-2 Receptors (α2)

Alpha-2 receptors (α2) are a class of adrenergic receptors that play a critical role in modulating sympathetic nervous system activity. Unlike alpha-1 receptors, which primarily mediate excitatory effects like smooth muscle contraction, alpha-2 receptors are generally inhibitory. They are involved in the regulation of neurotransmitter release, vascular tone, and various central nervous system functions. These receptors are also GPCRs and are divided into three subtypes: α2A, α2B, and α2C, each with distinct functions and tissue distributions.[25]

Structure and Mechanism of Action; Alpha-2 receptors are coupled to the Gi family of G proteins. Activation of these receptors by catecholamines such as norepinephrine leads to the inhibition of adenylyl cyclase, which decreases the production of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate. The reduction in cAMP levels results in decreased activation of protein kinase A (PKA), which in turn reduces phosphorylation of downstream targets, leading to various inhibitory effects.[26]

- Inhibition of Neurotransmitter Release: A key function of α2 receptors, particularly the α2A subtype, is the inhibition of neurotransmitter release. This is achieved by reducing cAMP levels, which leads to decreased calcium influx through voltage-gated calcium channels. As a result, the release of norepinephrine and other neurotransmitters is diminished, providing a negative feedback mechanism that helps regulate sympathetic nervous system activity.[26]
- Hyperpolarization of Neurons: Activation of α2 receptors can also lead to the opening of potassium channels, resulting in the hyperpolarization of neurons. This makes it more difficult for the neuron to fire action potentials, thereby reducing excitability and further inhibiting neurotransmitter release.[25]

Alpha-2 Receptor Subtypes

Each α2 receptor subtype (α2A, α2B, α2C) has specific roles depending on its tissue distribution and function, contributing to the regulation of various physiological processes.

Alpha-2A Receptors (α2A): α2A receptors are widely expressed in the CNS, particularly in the brainstem, spinal cord, and locus coeruleus. They are also found in presynaptic nerve terminals of the sympathetic nervous system.[25]

- Physiological Role: The α2A subtype is primarily responsible for the inhibitory effects on neurotransmitter release, acting as an autoreceptor. It plays a crucial role in modulating sympathetic outflow, reducing norepinephrine release, and thus dampening sympathetic nervous system activity. In the CNS, α2A receptors contribute to sedation, analgesia, and anxiolytic effects, making them a target for certain sedative and anesthetic drugs.[27]
- Clinical Significance: Drugs like clonidine, an α2 agonist, target α2A receptors to lower blood pressure by reducing sympathetic outflow. These receptors are also involved in the sedative effects of drugs like dexmedetomidine, used in anesthesia.[28]

Alpha-2B Receptors (α2B)

Tissue Distribution: α2B receptors are primarily found in peripheral tissues, including the vascular smooth muscle and some regions of the CNS.[25]

- Physiological Role: The α2B subtype is associated with vasoconstriction, particularly in the peripheral vasculature. While generally less involved in neurotransmitter release regulation, α2B receptors contribute

to the maintenance of vascular tone and blood pressure regulation.[25]

- Clinical Significance: α2B receptors play a role in the hypertensive response seen with some α2 agonists, which may be an initial effect before the central α2A-mediated blood pressure-lowering effects take over. Understanding the role of α2B receptors is important for managing side effects in treatments involving α2 agonists.[29]

Alpha-2C Receptors (α2C)

Tissue Distribution: α2C receptors are expressed in various tissues, including the CNS (especially in the basal ganglia and hippocampus), vascular smooth muscle, and the adrenal medulla.

- Physiological Role: The α2C subtype is involved in modulating neurotransmitter release, particularly under conditions of low temperature, stress, or altered neurotransmitter levels. In the CNS, α2C receptors have roles in cognitive function, mood regulation, and stress responses.[30]
- Clinical Significance: α2C receptors are of interest in research on psychiatric and neurodegenerative disorders, where dysregulation of adrenergic signaling might play a role. Drugs that target α2C receptors could have therapeutic potential in conditions like depression, schizophrenia, and Parkinson's disease.[30]

Beta-1 Receptors (β1)

Beta-1 receptors (β1) are a subtype of adrenergic receptors primarily associated with the regulation of heart function and metabolic processes. These receptors are crucial targets in the treatment of cardiovascular diseases, particularly heart failure and hypertension. As GPCRs, β1 receptors are activated by catecholamines like norepinephrine and epinephrine, leading to various physiological responses that are vital for maintaining cardiac output and metabolic homeostasis.[31]

Structure and Mechanism of Action

Beta-1 receptors are coupled to the Gs family of the G proteins. Upon activation by catecholamines, β1 receptors stimulate the Gs protein, which then activates adenylyl cyclase. This enzyme catalyzes the conversion of adenosine triphosphate to cAMP, a second messenger that plays a critical role in cellular signaling.[32]

cAMP Production: The increase in cAMP levels activates PKA, which phosphorylates various proteins within the cell, leading to enhanced calcium influx through L-type calcium channels in cardiac myocytes. This increased calcium availability is essential for cardiac muscle contraction.[33]

Cardiac Effects: Activation of β1 receptors in the heart leads to positive inotropic (increased force of contraction), chronotropic and dromotropic effects. These actions collectively enhance cardiac output, which is critical during stress or exercise when the body demands more oxygen and nutrients.[34]

Renin Release: In the kidneys, β1 receptors are located in the juxtaglomerular cells, where they stimulate the release of renin. Renin is a key enzyme in the renin-angiotensin-aldosterone system, which regulates blood pressure and fluid balance.[35]

Tissue Distribution and Physiological Role

Beta-1 receptors are predominantly expressed in the heart, kidneys, and adipose tissue. Their distribution and function make them central to the body's response to stress and the regulation of cardiovascular and metabolic systems.

Heart: Positive Inotropic Effect: β1 receptors are abundant in the myocardium (heart muscle), where their activation increases the force of cardiac contraction. This is achieved through the cAMP-mediated increase in intracellular calcium, which enhances the contractility of cardiac muscle fibers. Positive Chronotropic Effect[34]: β1 receptors are also present in the sinoatrial node, the natural pacemaker of the heart. Activation of β1 receptors increases the heart rate by accelerating the pacemaker activity of the sinoatrial node. Positive Dromotropic Effect: In the atrioventricular node, β1 receptor activation enhances the speed of electrical conduction,

Adipose Tissue: Lipolysis: β1 receptors in adipose tissue contribute to the regulation of fat metabolism. Activation of these receptors stimulates lipolysis, the breakdown of triglycerides into free fatty acids and glycerol, providing energy during periods of increased demand, such as exercise or fasting.[36]

Clinical Significance: While not the primary target for obesity treatments, the role of β1 receptors in lipolysis is an area of interest for understanding metabolic regulation and energy balance.

Beta-2 Receptors (β2)

Beta-2 receptors (β2) are a subtype of adrenergic receptors primarily involved in the regulation of smooth muscle relaxation, metabolic processes, and certain aspects of cardiovascular function. These receptors are distributed throughout various tissues in the body, including the lungs, skeletal muscle, liver, and vasculature. Their activation leads to diverse physiological responses, making them critical targets in the treatment of conditions such as asthma, chronic obstructive pulmonary disease (COPD), and preterm labor.[37]

Structure and Mechanism of Action; Beta-2 receptors are GPCRs linked to the Gs protein. Upon activation by catecholamines like epinephrine, β2 receptors stimulate the Gs protein, which in turn activates adenylyl cyclase. This activation leads to an increase in cAMP levels, a key second messenger involved in various cellular processes.[38]

cAMP Production: Elevated cAMP activates PKA, which phosphorylates target proteins within the cell, leading to the relaxation of smooth muscle, increased glucose metabolism, and other effects.[39]

Smooth Muscle Relaxation: One of the most prominent effects of β2 receptor activation is the relaxation of smooth muscle, particularly in the bronchi, vasculature, and uterus. This makes β2 receptors essential in the regulation of airway tone, vascular resistance, and uterine contractions.

Metabolic Effects: β2 receptors play a significant role in the regulation of glucose and lipid metabolism, particularly during the body's "fight or flight" response, where energy needs are heightened.[40]

Tissue Distribution and Physiological Role; Beta-2 receptors are widely distributed across various tissues, each contributing to specific physiological functions:

Lungs (Bronchial Smooth Muscle): Bronchodilation: β2 receptors are highly expressed in the bronchial smooth muscle of the lungs. When activated, these receptors induce bronchodilation, which widens the airways and facilitates airflow. This effect is crucial in conditions like asthma and COPD, where bronchoconstriction impairs breathing.[40]

Clinical Significance: The role of β2 receptors in bronchodilation makes them a primary target in the treatment of obstructive airway diseases. β2 agonists, such as albuterol and salmeterol, are commonly used as bronchodilators to relieve symptoms of asthma and COPD.[41]

Skeletal Muscle: Vasodilation: In skeletal muscle, β2 receptors mediate vasodilation, which increases blood flow to the muscles during exercise or stress. This helps the body to meet the heightened oxygen and nutrient demands of active muscles.[42]

Glycogenolysis: β2 receptors also promote glycogenolysis, the breakdown of glycogen into glucose, in skeletal muscle. This provides a rapid source of energy during periods of increased physical activity. Clinical Significance: The metabolic and vascular effects of β2 receptors in skeletal muscle are important in the body's response to stress and exercise, although they are less commonly targeted in pharmacotherapy.[43]

Liver: Glycogenolysis and Gluconeogenesis: In the liver, β2 receptor activation stimulates glycogenolysis and gluconeogenesis, processes that increase blood glucose levels. This is part of the body's acute stress response, ensuring that sufficient glucose is available for energy.[43]

Vasculature: Vasodilation: β2 receptors are also present in the vascular smooth muscle, where they mediate vasodilation, particularly in the coronary and skeletal muscle arteries. This

effect helps regulate blood flow during exercise and stress.

Uterus: Uterine Relaxation: β2 receptors in the uterus mediate relaxation of the uterine smooth muscle, which can help delay premature labor by reducing uterine contractions.

Clinical Significance: β2 agonists, such as terbutaline, are used as tocolytics to prevent or delay preterm labor by inhibiting uterine contractions, although their use has declined due to potential side effects.

Beta-3 Receptors (β3)

Beta-3 receptors (β3) are a subtype of adrenergic receptors primarily associated with the regulation of metabolic processes, particularly in adipose tissue, the bladder, and the cardiovascular system. Unlike β1 and β2 receptors, which are more involved in cardiovascular and respiratory functions, β3 receptors are predominantly linked to energy metabolism, thermogenesis, and lipolysis. They are increasingly being studied for their potential role in treating obesity, type 2 diabetes, and overactive bladder syndrome.[38]

Structure and Mechanism of Action

Beta-3 receptors are GPCRs linked to the Gs protein, similar to other beta receptors. However, they can also couple with Gi proteins in certain tissues, leading to a more complex array of signaling outcomes. When activated by catecholamines like norepinephrine, β3 receptors stimulate adenylyl cyclase, leading to an increase in cAMP levels.[31]

cAMP Production: Elevated cAMP levels activate PKA, which phosphorylates various target proteins, leading to the activation of enzymes involved in lipolysis and thermogenesis, particularly in adipose tissue.[33]

Thermogenesis: One of the hallmark functions of β3 receptors is the stimulation of thermogenesis in brown adipose tissue. This process involves the generation of heat through the oxidation of fatty acids, contributing to the regulation of body temperature and energy expenditure.[44]

Lipolysis: In white adipose tissue, β3 receptor activation promotes the breakdown of triglycerides into free fatty acids and glycerol, providing energy and contributing to fat loss.

Tissue Distribution and Physiological Role

Beta-3 receptors are primarily found in adipose tissue but are also present in other tissues, including the bladder and the cardiovascular system. Their distribution highlights their role in metabolic regulation and bladder function.[45]

Immunology of the Adrenergic Anti-Inflammatory Pathway

The adrenergic anti-inflammatory pathway represents a crucial interface between the nervous and immune systems, where the autonomic nervous system, through adrenergic signaling, modulates immune responses and inflammation. This pathway involves adrenergic receptors, primarily the β2 adrenergic receptor, but also includes other adrenergic receptor subtypes, such as α2 receptors, and their role in regulating immune cell activity, cytokine production, and overall inflammation.[46]

Mechanism of Adrenergic Modulation of Immune Responses

Adrenergic Receptors on Immune Cells: Distribution: Adrenergic receptors, particularly β2 and α2 receptors, are expressed on various immune cells, including T cells [47], B cells, macrophages, dendritic cells, and natural killer cells. The expression of these receptors allows the nervous system to exert direct influence over the immune system.[48]

Activation by Catecholamines: The primary endogenous agonists for adrenergic receptors are the catecholamines, epinephrine and norepinephrine. These neurotransmitters are released in response to stress or activation of the sympathetic nervous system and can bind to adrenergic receptors on immune cells, triggering specific signaling pathways.[48]

Beta-2 Adrenergic Receptor (β2-AR) in Immune Modulation: Upon binding of catecholamines to β2-AR on immune cells, the receptor activates the Gs protein, leading to increased levels of intracellular cAMP. This

elevation in cAMP can have several downstream effects on immune cell function.[49]

Inhibition of Pro-inflammatory Cytokines: β2-AR activation is known to suppress the production of pro-inflammatory cytokines, such as tumor necrosis factor-α, interleukin (IL)-1β, and IL-6, in macrophages and dendritic cells. This anti-inflammatory effect is mediated through the cAMP-PKA signaling pathway, which can inhibit the activation of nuclear factor-kappa B, a key transcription factor involved in the expression of inflammatory genes.[50]

Promotion of Anti-inflammatory Cytokines: In addition to inhibiting pro-inflammatory cytokines, β2-AR activation can enhance the production of anti-inflammatory cytokines, such as IL-10. This shift in the cytokine balance helps to resolve inflammation and promote tissue healing.[51]

Regulation of T Cell Activity: β2-AR activation on T cells can lead to the suppression of Th1 responses, which are typically associated with pro-inflammatory activities, and the promotion of Th2 responses, which are more anti-inflammatory in nature.[52] This modulation of T cell activity contributes to the overall anti-inflammatory effects of adrenergic signaling.

Impact on Macrophages and Dendritic Cells: In macrophages, β2-AR activation can polarize these cells toward an anti-inflammatory M2 phenotype, characterized by enhanced tissue repair and reduced inflammatory responses.[50] In dendritic cells, β2-AR activation can reduce the ability of these cells to present antigens and activate T cells, thereby dampening adaptive immune responses.

Alpha-2 Adrenergic Receptor (α2-AR) in Immune Modulation: Inhibition of cAMP Production: α2-ARs are coupled to the Gi protein, which inhibits adenylyl cyclase, leading to reduced cAMP levels. The impact of α2-AR activation on immune responses is more context-dependent and can vary based on the cell type and the presence of other signaling pathways.[53]

Suppression of Inflammatory Responses: Similar to β2-AR, α2-AR activation can also result in the suppression of pro-inflammatory cytokine production, though the mechanisms may differ. α2-AR activation is particularly relevant in the regulation of inflammatory responses in conditions of stress or chronic inflammation.[54]

Role in Immune Cell Trafficking: α2-ARs are also involved in the regulation of immune cell trafficking and migration. Their activation can influence the movement of immune cells to sites of inflammation, thereby modulating the intensity and duration of the immune response.[46]

Clinical Implications and Therapeutic Potential

Autoimmune Diseases: Modulation of Autoimmune Responses: The adrenergic anti-inflammatory pathway has significant implications for the treatment of autoimmune diseases, where dysregulated immune responses cause tissue damage. By targeting β2-ARs, it may be possible to reduce the severity of autoimmune responses and ameliorate disease symptoms.[55]

Therapeutic Use of β2 Agonists: Drugs that activate β2-ARs, such as selective β2 agonists, could be explored as potential therapies for autoimmune diseases like rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, where inflammation plays a central role.[55]

Sepsis and Systemic Inflammation: Counteracting Hyperinflammation: In sepsis, an uncontrolled inflammatory response can lead to organ damage and death. The adrenergic anti-inflammatory pathway may help to counteract this hyperinflammation by suppressing pro-inflammatory cytokine production and enhancing anti-inflammatory mechanisms.

Potential for Adrenergic Modulation in Sepsis: While adrenergic drugs are already used in the management of sepsis for their cardiovascular effects, their role in directly modulating the immune response could provide additional therapeutic benefits, potentially improving outcomes in septic patients.[56]

Chronic Inflammatory Diseases: Asthma and COPD: In conditions like asthma and COPD, where chronic inflammation contributes to disease progression, β2 agonists are already used for their bronchodilatory effects. However, their anti-inflammatory properties through β2-AR activation on immune cells also play a role in controlling inflammation in the airways.[41]

Inflammatory Bowel Disease: The anti-inflammatory effects of adrenergic signaling could be harnessed in the treatment of inflammatory bowel disease, where inflammation of the gastrointestinal tract leads to chronic symptoms. Modulating adrenergic pathways may provide a novel approach to managing these conditions.[57]

Cancer and Tumor Immunology: Impact on Tumor Microenvironment: Adrenergic signaling can influence the tumor microenvironment by modulating immune cell activity. β2-AR activation in tumor-associated macrophages and other immune cells can shift the balance between pro- and anti-tumor immune responses.[58]

Potential for Immunotherapy: Understanding the role of adrenergic signaling in the tumor microenvironment could lead to the development of new strategies that either enhance or inhibit this pathway to improve cancer immunotherapy outcomes.

Research and Future Directions

Biased Agonism: The concept of biased agonism, where a drug preferentially activates certain signaling pathways over others, is gaining interest in adrenergic pharmacology. For instance, a biased agonist might selectively trigger beneficial pathways (such as those involved in anti-inflammatory responses) while avoiding pathways that lead to side effects. This approach has the potential to create more effective and safer drugs.[59]

Crosstalk with Other Signaling Pathways: Adrenergic receptors do not function in isolation; they often interact with other signaling pathways, such as those mediated by inflammatory cytokines or other GPCRs. Investigating these interactions could reveal new therapeutic strategies for diseases where adrenergic signaling plays a role in pathology, such as heart failure, chronic inflammation, and metabolic disorders.

Genetic Variability and Personalized Medicine: Genetic differences in adrenergic receptor expression and function can influence an individual's response to drugs targeting these pathways. Pharmacogenomics is exploring how these genetic variations can be used to tailor treatments to individual patients, optimizing therapeutic outcomes and minimizing adverse effects.[60]

Conclusion

The adrenergic pathways are a cornerstone of physiological regulation, influencing critical processes such as cardiovascular function, respiratory dynamics, and metabolic balance. The pharmacological manipulation of these pathways has revolutionized the treatment of many diseases, and ongoing research continues to expand our understanding of their complexity and therapeutic potential. As the field advances, the development of more selective and personalized therapeutic strategies will likely enhance our ability to treat conditions ranging from cardiovascular and respiratory diseases to metabolic disorders, improving patient outcomes across a wide spectrum of clinical contexts.

Author Contributions

AAA and IMS; reviewed conception & design; wrote original draft; and writing review & editing.

References

1. LeBouef T YZ, Whited L. (2024). Physiology, Autonomic Nervous System. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538516/.

2. Westfall TC. (2009). Sympathomimetic Drugs and Adrenergic Receptor Antagonists. Encyclopedia of Neuroscience. Squire LR (ed): Academic Press, Oxford;. 685-695. https://doi.org/10.1016/B978-008045046-9.01156-6

3. He X, Du T, Long T, et al.(2022). Signaling cascades in the failing heart and emerging therapeutic

strategies. Signal Transduction and Targeted Therapy., 7:134. 10.1038/s41392-022-00972-6

4. Ma J, Li Y, Yang X, et al. (2023). Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy., 8:168. 10.1038/s41392-023-01430-7

5. Koziol-White CJ, Panettieri RA, Jr. (2019). Modulation of Bronchomotor Tone Pathways in Airway Smooth Muscle Function and Bronchomotor Tone in Asthma. Clinics in chest medicine., 40:51-57. 10.1016/j.ccm.2018.10.003

6. Barella LF, Jain S, Kimura T, et al. (2021). Metabolic roles of G protein-coupled receptor signaling in obesity and type 2 diabetes. The FEBS Journal., 288:2622-2644. https://doi.org/10.1111/febs.15800

7. Martínez-Milla J, Raposeiras-Roubín S, Pascual-Figal DA, et al.: (2019). Role of Beta-blockers in Cardiovascular Disease in 2019. Revista Española de Cardiología (English Edition)., 72:844-852. 10.1016/j.rec.2019.04.014

8. Billington CK, Penn RB, Hall IP. (2017). β(2) Agonists. Handbook of experimental pharmacology., 237:23-40. 10.1007/164_2016_64

9. Chhatar S, Lal G. (2021). Role of adrenergic receptor signalling in neuroimmune communication. Current Research in Immunology., 2:202-217. https://doi.org/10.1016/j.crimmu.2021.11.001

10. Benovic JL: Novel β₂-adrenergic receptor signaling pathways. Journal of Allergy and Clinical Immunology. 2002, 110:S229-S235. 10.1067/mai.2002.129370

11. Paravati S RA, Warrington SJ. (2024). Physiology, Catecholamines. [Updated 2022 Oct 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507716/.

12. Perez DM. (2020). α(1)-Adrenergic Receptors in Neurotransmission, Synaptic Plasticity, and Cognition. Frontiers in pharmacology., 11:581098. 10.3389/fphar.2020.581098

13. Hein L, Kobilka BK. (1997). Adrenergic Receptors From Molecular Structure to in vivo function. Trends in Cardiovascular Medicine., 7:137-145. https://doi.org/10.1016/S1050-1738(97)00034-0

14. Rehman S RN, Dimri M. (2024). Biochemistry, G Protein Coupled Receptors. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK518966/.

15. Boczek T, Mackiewicz J, Sobolczyk M, et al. (2021). The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines. Cells., 10:1228.

16. Prole DL, Taylor CW. (2019). Structure and Function of IP(3) Receptors. Cold Spring Harbor perspectives in biology., 11. 10.1101/cshperspect.a035063

17. Foskett JK, White C, Cheung KH, et al. (2007). Inositol trisphosphate receptor Ca2+ release channels. Physiological reviews., 87:593-658. 10.1152/physrev.00035.2006

18. Lau BW, Colella M, Ruder WC, et al. (2005). Deoxycholic acid activates protein kinase C and phospholipase C via increased Ca²⁺ entry at plasma membrane. Gastroenterology., 128:695-707. 10.1053/j.gastro.2004.12.046

19. Schwinn DA, Roehrborn CG. (2008). Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. International journal of urology : official journal of the Japanese Urological Association., 15:193-199. 10.1111/j.1442-2042.2007.01956.x

20. Michel MC, Vrydag W. (2006). Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. British journal of pharmacology., 147 Suppl 2:S88-119. 10.1038/sj.bjp.0706619

21. Jensen BC, Swigart PM, Montgomery MD, et al. (2010). Functional alpha-1B adrenergic receptors on human epicardial coronary artery endothelial cells. Naunyn-Schmiedeberg's archives of pharmacology., 382:475-482. 10.1007/s00210-010-0558-x

22. Li H, Xu TY, Li Y, et al. (2022). Role of α1-blockers in the current management of hypertension. Journal of clinical hypertension (Greenwich, Conn)., 24:1180-1186. 10.1111/jch.14556

23. Jensen BC, Swigart PM, Laden ME, et al. (2009). The alpha-1D Is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries. Journal of the American College of Cardiology., 54:1137-1145. 10.1016/j.jacc.2009.05.056

24. Lyssand JS, DeFino MC, Tang XB, et al. (2008). Blood pressure is regulated by an alpha1D-adrenergic receptor/dystrophin signalosome. The Journal of biological chemistry., 283:18792-18800. 10.1074/jbc.M801860200

25. Giovannitti JA, Jr., Thoms SM, Crawford JJ. (2015). Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesthesia progress., 62:31-39. 10.2344/0003-3006-62.1.31

26. Taylor BN CMA-ARUJISITIFSPJ-Af.

27. Wang B WY, Wu Q, Huang HP and Li S (2017). Effects of α2A Adrenoceptors on Norepinephrine Secretion from the Locus Coeruleus during Chronic

Stress-Induced Depression. Front. Neurosci. 11:243. doi: 10.3389/fnins.2017.00243.

28. Yasaei R SACUJISITIFSPJ-Afh.

29. Hering L, Rahman M, Potthoff SA, et al. (2020). Role of α2-Adrenoceptors in Hypertension: Focus on Renal Sympathetic Neurotransmitter Release, Inflammation, and Sodium Homeostasis. Frontiers in physiology., 11:566871. 10.3389/fphys.2020.566871

30. Uys MM, Shahid M, Harvey BH. (2017). Therapeutic Potential of Selectively Targeting the α(2C)-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective. Frontiers in psychiatry., 8:144. 10.3389/fpsyt.2017.00144

31. Alhayek S PCBRUAISITIFSPJ-Af: Beta 1 Receptors. [Updated 2023 Aug 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532904/.

32. Vasudevan NT, Mohan ML, Goswami SK, et al. (2011). Regulation of β-adrenergic receptor function: an emphasis on receptor resensitization. Cell cycle (Georgetown, Tex)., 10:3684-3691. 10.4161/cc.10.21.18042

33. Liu Y, Chen J, Fontes SK, et al. (2022). Physiological and pathological roles of protein kinase A in the heart. Cardiovascular research., 118:386-398. 10.1093/cvr/cvab008

34. Gordan R, Gwathmey JK, Xie LH. (2015). Autonomic and endocrine control of cardiovascular function. World journal of cardiology., 7:204-214. 10.4330/wjc.v7.i4.204

35. Kelley E, Phelps P, Akre M, et al. (2019). The Influence of β1-Adrenergic Receptor Genotype of Renal Sodium Handling and Blood Pressure Response to Angiotensin Receptor Blockers in Hypertension Patients. The FASEB Journal., 33:819.815-819.815. https://doi.org/10.1096/fasebj.2019.33.1_supplement.819.5

36. Collins S. (2022). β-Adrenergic Receptors and Adipose Tissue Metabolism: Evolution of an Old Story. Annual review of physiology., 84:1-16. 10.1146/annurev-physiol-060721-092939

37. Abosamak NER SMBRAaAUJISITIFSPJ-A.

38. Motiejunaite J, Amar L, Vidal-Petiot E. (2021). Adrenergic receptors and cardiovascular effects of catecholamines. Annales d'Endocrinologie., 82:193-197. https://doi.org/10.1016/j.ando.2020.03.012

39. Manni S, Mauban JH, Ward CW, et al. (2008). Phosphorylation of the cAMP-dependent protein kinase (PKA) regulatory subunit modulates PKA-AKAP interaction, substrate phosphorylation, and calcium signaling in cardiac cells. The Journal of biological chemistry., 283:24145-24154. 10.1074/jbc.M802278200

40. Man KNM, Navedo MF, Horne MC, et al. (2020). β(2) Adrenergic Receptor Complexes with the L-Type Ca(2+) Channel Ca(V)1.2 and AMPA-Type Glutamate Receptors: Paradigms for Pharmacological Targeting of Protein Interactions. Annual review of pharmacology and toxicology., 60:155-174. 10.1146/annurev-pharmtox-010919-023404

41. Yang A, Yu G, Wu Y, et al. (2021). Role of β2-adrenergic receptors in chronic obstructive pulmonary disease. Life Sciences., 265:118864. https://doi.org/10.1016/j.lfs.2020.118864

42. Joyner MJ, Casey DP. (2015). Regulation of increased blood flow (hyperemia) to muscles during exercise: a hierarchy of competing physiological needs. Physiological reviews., 95:549-601. 10.1152/physrev.00035.2013

43. Katz MS, Dax EM, Gregerman RI. (1993). Beta adrenergic regulation of rat liver glycogenolysis during aging. Experimental Gerontology., 28:329-340. https://doi.org/10.1016/0531-5565(93)90060-Q

44. Cero C, Lea HJ, Zhu KY, et al. (2021). β3-Adrenergic receptors regulate human brown/beige adipocyte lipolysis and thermogenesis. JCI insight., 6. 10.1172/jci.insight.139160

45. Duncan RE, Ahmadian M, Jaworski K, et al. (2007). Regulation of lipolysis in adipocytes. Annual review of nutrition., 27:79-101. 10.1146/annurev.nutr.27.061406.093734

46. Sharma D, Farrar JD. (2020). Adrenergic regulation of immune cell function and inflammation. Seminars in immunopathology. 42:709-717. 10.1007/s00281-020-00829-6

47. Farooq MA, Ajmal I, Hui X, et al. (2023). β2-Adrenergic Receptor Mediated Inhibition of T Cell Function and Its Implications for CAR-T Cell Therapy. International journal of molecular sciences., 24. 10.3390/ijms241612837

48. Chhatar S, Lal G. (2021). Role of adrenergic receptor signalling in neuroimmune communication. Curr Res Immunol., 2:202-217. 10.1016/j.crimmu.2021.11.001

49. Billington CK, Penn RB. (2003). Signaling and regulation of G protein-coupled receptors in airway smooth muscle. Respiratory research., 4:2.

50. Freire BM, de Melo FM, Basso AS. (2022). Adrenergic signaling regulation of macrophage function: do we understand it yet? Immunotherapy advances., 2:ltac010. 10.1093/immadv/ltac010

51. Ağaç D, Estrada LD, Maples R, et al. (2018). The β2-adrenergic receptor controls inflammation by

driving rapid IL-10 secretion. Brain, behavior, and immunity., 74:176-185. 10.1016/j.bbi.2018.09.004

52. Nijhuis LE, Olivier BJ, Dhawan S, et al. (2014). Adrenergic β2 receptor activation stimulates anti-inflammatory properties of dendritic cells in vitro. PloS one., 9:e85086. 10.1371/journal.pone.0085086

53. Renauld AE, Ignatowski TA, Spengler RN. (2004). α2-Adrenergic receptor inhibition of cAMP accumulation is transformed to facilitation by tumor necrosis factor-α. Brain Research., 1004:212-216. https://doi.org/10.1016/j.brainres.2004.01.029

54. Walsh CP, Bovbjerg DH, Marsland AL. (2021). Glucocorticoid resistance and β2-adrenergic receptor signaling pathways promote peripheral pro-inflammatory conditions associated with chronic psychological stress: A systematic review across species. Neuroscience & Biobehavioral Reviews. 128:117-135.
https://doi.org/10.1016/j.neubiorev.2021.06.013

55. Lv J, Ji X, Li Z, et al. (2021). The role of the cholinergic anti-inflammatory pathway in autoimmune rheumatic diseases. Scandinavian Journal of Immunology. 94:e13092. https://doi.org/10.1111/sji.13092

56. Zhang JM, An J, (2007). Cytokines, inflammation, and pain. International anesthesiology clinics. 2007, 45:27-37. 10.1097/AIA.0b013e318034194e

57. Serafini MA, Paz AH, Nunes NS, (2022). Cholinergic immunomodulation in inflammatory bowel diseases. Brain, behavior, & immunity - health. 19:100401. 10.1016/j.bbih.2021.100401

58. Wang W, Cao X. (2019). Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy. Critical reviews in immunology., 39:93-103. 10.1615/CritRevImmunol.2019031188

59. Franco R, Aguinaga D, Jiménez J, et al. (2018). Biased receptor functionality versus biased agonism in G-protein-coupled receptors. Biomolecular Concepts., 9:143-154. doi:10.1515/bmc-2018-0013

60. Hesse C, Eisenach JH, (2008). Genetic Variation In The B(2)-Adrenergic Receptor: Impact On Intermediate Cardiovascular Phenotypes. Current pharmacogenomics and personalized medicine., 6:160-170. 10.2174/1875692110806030160